Samsung Biologics (KRX:207940) extended its partnership with LigaChem Biosciences to provide antibody-drug conjugate (ADC) services at its new ADC facility, the South Korean biotechnology firm said Thursday.
The collaboration focuses on ADC programs for solid tumor treatments. Samsung's facility, equipped with a 500-liter reactor, offers end-to-end ADC services from development to conjugation, using its expertise in large-scale antibody manufacturing, it said.
Shares of Samsung Biologics rose nearly 1% in recent trade on Friday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。